YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Combinatorial Effect of 5-FU and Epigenetic Silencing Repressors in Human Colorectal Cancer Cells

인체대장암 세포에서 후성적 유전자 불활성화 저해제와 5-Fluorouracil의 병용효과분석

  • Kim Mi-Young (Dept. of Biomedical Sciences, College of Medicine, The Catholic Univ. of Korea) ;
  • Son Jung-Kyu (Dept. of Biomedical Sciences, College of Medicine, The Catholic Univ. of Korea) ;
  • Lee Suk-Kyeong (Dept. of Biomedical Sciences, College of Medicine, The Catholic Univ. of Korea) ;
  • Ku Hyo-Jeong (Dept. of Biomedical Sciences, College of Medicine, The Catholic Univ. of Korea)
  • 김미영 (가톨릭대학교 의과대학 생명의과학과) ;
  • 손정규 (가톨릭대학교 의과대학 생명의과학과) ;
  • 이숙경 (가톨릭대학교 의과대학 생명의과학과) ;
  • 구효정 (가톨릭대학교 의과대학 생명의과학과)
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Low sensitivity to anticancer drugs such as 5-fluorouracil (5-FU) has been associated with decreased expression of genes involved in cell proliferation, apoptosis and metastasis. Recently, it has been shown that the expression levels of some of these genes are reduced by transcription inhibition due to epigenetic silencing on CpG islands. Therefore, epigenetic therapy has been proposed, where epigenetic silencing is repressed with DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors alone or in combination with other chemotherapeutic agents. The aim of our study was to evaluate the combination effect of 5-FU and its association with the status of epigenetic silencing using methylation-specific PCR of $p14^{ARF}$ when given with S-aza-2'-deoxycytidine (5-aza-dC), a DNMT inhibitor and depsipeptide, an HDAC inhibitor in DLD-1 human colorectal cancer cells. The combination of 5-aza-dC with depsipeptide showed a synergism and induced unmethylation of $p14^{ARF}$. However, triplet combination of 5-aza-dc/depsipeptide and 5-FU resulted in antagonistic effects and abrogated unmethylation of $p14^{ARF}$. These results suggest that unfavorable interaction of 5-aza-dC/depsipeptide with 5-FU in DLD-1 cells may be related with the failure in repression of epigenetic silencing, which warrants further investigation.

Keywords

References

  1. Icli, F. and Arican, A. : Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant 5-fluorouracil. Oncology 5694, 297 (1999)
  2. Kessinger, M. A., Foley, J. F and Lemon, H. M. ; Adriamycin, mitomycin C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil. Cancer. Clin. Trials 2, 317 (1979)
  3. Saga, Y, Suzuki, M., Mizukami, H., Kohno, T., Takei, Y., Fukushima, M. and Ozawa, K. : Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells. Int. J. Cancer 106, 324 (2003) https://doi.org/10.1002/ijc.11221
  4. Yoshinare, K., Kubota, T., Watanabe, M., Wada, N., Nishibori, H., Hasegawa, H., Kitajima, M., Takechi, T. and Fukushima, M.. : Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci. 94, 633 (2003) https://doi.org/10.1111/j.1349-7006.2003.tb01495.x
  5. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J. and Boothman, D. A. : Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 61, 5193 (2001)
  6. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A. M., Chambaz, J., Lacorte, J. M., Staedel, C. and Lesuffleur, T. : Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 98, 498 (2002) https://doi.org/10.1002/ijc.10146
  7. Li, M. H., Ito, D., Sanada, M., Odani, T., Hatori, M., Iwase, M. and Nagumo, M. : Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol. 40, 63 (2004) https://doi.org/10.1016/S1368-8375(03)00136-2
  8. Wolfgang, M. Schmidt and Maria Kalipciyan : Dissecting progressive stages of 5-Fluorouracil resistance in vitro using RNA expression profiling. Int. J. Cancer 112, 200 (2004) https://doi.org/10.1002/ijc.20401
  9. Nakamura, N. and Takenaga, K. : Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin. Exp. Metastasis 16, 471 (1998)
  10. Murai, M., Toyota, M., Suzuki, H., Satoh, A., Sasaki, Y., Akino, K., Ueno, M., Takahashi, F., Kusano, M., Mita, H., Yanagihara, K., Endo, T., Hinoda, Y., Tokino, T. and Irnai, K. : Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clincal Cancer Res. 11, 1021 (2005)
  11. Kopelovich, L., Crowell, J. A. and Fay, J. R. : The epigenome as a target for cancer chemoprevention. J. Natl. Cancer Inst. 95, 1747 (2003) https://doi.org/10.1093/jnci/dig109
  12. Zhu, W. G. and Otterson, G. A. : The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Canc. Agents 3, 187 (2003) https://doi.org/10.2174/1568011033482440
  13. Rice, J. C. and Allis, C. D. : Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr. Opin. Cell Biol. 3, 263 (2001) https://doi.org/10.1016/0955-0674(91)90158-U
  14. de Angelis, P. M., Fjell, B., Kravik, K. L., Haug, T., Tunheim, S. H., Reichelt, W., Beigi, M., Clausen, O. P., Galteland, E. and Stokke, T. : Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int. J. Oncol. 24, 1279 (2004)
  15. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. and Baylin, S. B. : Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821 (1996)
  16. Esteller, M., Tortola, S., Toyota, M., Capella, G., Peinado, M. A., Baylin, S. B. and Herman, J. G. : Hypermethylationassociated inactivation of $p14^{ARF}$ is in- depepdent of $p16^{INK4a}$ methylation and p53 mutational status. Cancer Res. 50, 129 (2000)
  17. Chou, T.-C. and Talalay, P. : Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27 (1984) https://doi.org/10.1016/0065-2571(84)90007-4
  18. Longley, D. B., Harkin, D. P. and Johnston, P. G. : 5-fluorouracil: mechanism of action and clinical strategies. Nature 3, 330 (2003) https://doi.org/10.1038/nmat1116
  19. Kanda, T., Tada, M., Imazeki, F., Yokosuka, O., Nagao, K. and Saisho, H. : 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol. Rep. 14, 975 (2005)
  20. Momparler, R. L. : Pharmacology of 5-aza-2'-deoxycytidine (decitabine) Semin. Hematol. 42, 9 (2005)
  21. Xiao, J. J., Foraker, A. B., Swaan, P. W., Liu, S., Huang, Y., Dai, Z., Chen, J., Sadee, W., Byrd, J., Marcucci, G. and Chan, K K. : Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 313, 268 (2005) https://doi.org/10.1124/jpet.104.072033
  22. Murata, M., Towatari, M., Kosugi, H., Tanimoto, M., Ueda, R., Saito, H. and Naoe, T. : Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn. J. Cancer Res. 91, 1154 (2000) https://doi.org/10.1111/j.1349-7006.2000.tb00899.x
  23. Nakumura, T., Sakaeda, T., Ohmoto, N., Moriya, Y, Komoto, C., Shirakawa, T., Gotoh, A., Matsuo, M. and Okmura, K. : Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm. Res. 20, 324 (2003) https://doi.org/10.1023/A:1022251910820
  24. Primeau, M., Gagnon, J. and Momparler, R. L. : Synegistic antineoplastic action of DNA methylation inhibitor 5-aza-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 103, 177 (2003) https://doi.org/10.1002/ijc.10789
  25. Gagnon, J., Shake, S., Primeau, M., Hurtubise, A. and Momparler, R. L. : Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14, 193 (2003) https://doi.org/10.1097/00001813-200303000-00002
  26. Arnold, C. N., Goel, A. and Boland, C. R. : Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorourcil in colorectal cancer cell lines. Int. J. Cancer 106, 66 (2003) https://doi.org/10.1002/ijc.11176